Matthew J. Jackson, PhD, is a Research Fellow at the Center for Integration of Science and Industry at Bentley University. He received a BSc in Pharmacology from the University of Dundee and an MSc in Stratified Medicine and Pharmacological Innovation from the University of Glasgow. He gained his PhD in Cellular Medicine from Newcastle University, UK, investigating effects of oxidative damage on cellular bioenergetics in the ageing skin and worked with Hexis Labs Ltd and Newcastle University in a Knowledge Transfer Partnership associate role. At Bentley, his research interests focus on trends in new drug discovery including funding of R&D and societal impact of pharmaceutical activity. In addition to his current research, he also holds an adjunct professor role at Bentley University, teaching Human Biology within the department of Natural and Applied Sciences.
By this expert
Gilead’s shareholders want exorbitant profits from Remdesivir, even though it was the public that enabled its development.
New research points to critical role of public funding in drug discoveries and development for the last decade